GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow

November 19, 2013 updated by: MD ph.d. Lasse Bremholm, Zealand University Hospital

GLP-1's Influence on Intestinal Blood Flow

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters, in healthy subjects, 4 arms, task force monitor

Study Type

Interventional

Enrollment (Anticipated)

8

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
    • State...
      • Køge, State..., Denmark, 4600
        • Recruiting
        • Køge Hospital
        • Contact:
        • Principal Investigator:
          • Lasse Bremholm, MD, ph.d.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 76 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • medical conditions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: GLP-1
1,5 nmol/kg,GLP-1 sc injection
Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection
Other: Exendin-4 ;10 ug,sc injection
Active Comparator: GLP-1 9-36amide
1,5 nmol/kg GLP-1 9-36amide, sc injection
Other: Exendin-4 ;10 ug,sc injection
Other: 1,5 nmol/kg,GLP-1 sc injection
Other Names:
  • native GLP-1
Active Comparator: Exendin-4
Exendin-4 ;10 ug,sc injection
Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection
Other: 1,5 nmol/kg,GLP-1 sc injection
Other Names:
  • native GLP-1
Placebo Comparator: isotonic saline
2 ml of isotonic saline, sc injection
Other: 1,5 nmol/kg GLP-1 9-36amide, sc injection
Other: 1,5 nmol/kg,GLP-1 sc injection
Other Names:
  • native GLP-1
Other: saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood flow
Time Frame: with in 120 minutes
blood flow change measured by ultra sound
with in 120 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
cardiac parameters
Time Frame: with in 120 minutes
measure of cardiac change with task force monitor
with in 120 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zealand University Hospital

Collaborators

University of Copenhagen
Glostrup University Hospital, Copenhagen

Investigators

  • Principal Investigator: Lasse Bremholm, MD, ph.d., Køge Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2013

Primary Completion (Anticipated)

June 1, 2014

Study Completion (Anticipated)

December 1, 2014

Study Registration Dates

First Submitted

November 13, 2013

First Submitted That Met QC Criteria

November 19, 2013

First Posted (Estimate)

November 20, 2013

Study Record Updates

Last Update Posted (Estimate)

November 20, 2013

Last Update Submitted That Met QC Criteria

November 19, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2013.GLP-1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on 1,5 nmol/kg GLP-1 9-36amide, sc injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe